UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the
Securities Exchange Act of 1934
September
18, 2026
Commission
File Number 001-14978
SMITH & NEPHEW plc
(Registrant’s
name)
Building 5, Croxley Park, Hatters Lane
Watford, England, WD18 8YE
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F ✔
Form 40-F
__
Redemption of $350,000,000 5.150% Notes due 2027
Smith & Nephew plc
$350,000,000 5.150% Notes due 2027 (CUSIP: 83192PAC2, ISIN:
US83192PAC23) (the "Securities")
September 18, 2026. Smith &
Nephew plc (the "Issuer") announces that it has issued a notice of
redemption for the entire outstanding principal amount of the
Securities. A notice of redemption pursuant to the terms of the
Indenture dated October 14, 2020 governing the Securities has been
distributed to The Bank of New York Mellon, London Branch, as
Trustee (the "Trustee").
The outstanding Securities will be redeemed on October 5, 2026 (the
"Redemption
Date") at the redemption price
to be calculated in accordance with the terms of the Indenture (the
"Redemption
Price"). Accordingly, the
listing of the Securities on the New York Stock Exchange will be
cancelled on, or shortly after, October 5,
2026.
The location where Holders may surrender the Securities and obtain
payment of the Redemption Price is The Bank of New York Mellon,
London Branch, 160 Queen Victoria Street, London EC4V 4LA, United
Kingdom, Attn: Corporate Trust Administration.
On the Redemption Date, the Redemption Price will become due and
payable and interest on the Securities will cease to accrue. Before
the Redemption Date, the Issuer will irrevocably deposit with the
Trustee or with a Paying Agent an amount of money sufficient to pay
the total Redemption Price of each of the Securities. When the
Issuer makes such a deposit, all rights of holders of the
Securities will cease, except the holders' rights to receive the
Redemption Price, and unpaid interest and any additional amounts
due on the Redemption Date, and the Securities will no longer be
outstanding.
For further information in relation to the redemption of the
Securities, please contact:
Group Treasury:
Adam Richford
Group Treasurer
Telephone: +44 01923 477 100
Smith+Nephew Forward-looking Statements
This announcement contains certain "forward-looking" statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. For example, statements regarding expected revenue growth
and trading profit margins, market trends and our product pipeline
are forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: conflicts
in Europe and the Middle East, economic and financial conditions in
the markets we serve, especially those affecting healthcare
providers, payers and customers; price levels for established and
innovative medical devices; developments in medical technology;
regulatory approvals, reimbursement decisions or other government
actions; product defects or recalls or other problems with quality
management systems or failure to comply with related regulations;
litigation relating to patent or other claims; legal and financial
compliance risks and related investigative, remedial or enforcement
actions; disruption to our supply chain or operations or those of
our suppliers; competition for qualified personnel; strategic
actions, including acquisitions and disposals, our success in
performing due diligence, valuing and integrating acquired
businesses; disruption that may result from transactions or other
changes we make in our business plans or organization to adapt to
market developments; relationships with healthcare professionals;
reliance on information technology and cybersecurity; disruptions
due to natural disasters, weather and climate change related
events; changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; effects of AI use and deployment; and numerous
other matters that affect us or our markets, including those of a
political, economic, business, competitive or reputational nature.
Please refer to the documents that Smith+Nephew has filed with the
U.S. Securities and Exchange Commission under the U.S. Securities
Exchange Act of 1934, as amended, including Smith+Nephew's most
recent annual report on Form 20-F for the year ended December 31,
2025 and interim financial statements on Form 6-K for the six
months period ended June 27, 2026, which are available on the SEC's
website at www. sec.gov and the Offer to Purchase, for a discussion
of certain of these factors. Any forward-looking statement is based
on information available to Smith+Nephew as of the date of the
statement. The Company can give no assurance that any goal or plan
set forth in the Company's forward-looking statements will be
achieved and readers are cautioned not to place undue reliance on
such statements, which speak only as of the date made. All written
or oral forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
Smith & Nephew plc
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
|
Date:
September 18, 2026
|
By:
|
/s/
Helen Barraclough
|
|
|
|
Helen
Barraclough
|
|
|
|
Company
Secretary
|
